Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to tackle high blood pressure in black communities

NCT ID NCT05208450

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called PACE that combines nurse support, remote blood pressure monitoring, and help with social needs (like housing or food) to improve blood pressure control in Black patients. About 500 adults with uncontrolled high blood pressure will take part across 25 clinics in New York City. The goal is to see if this community-clinic approach can reduce health disparities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Practice support and community engagement program (nurse case management, remote blood pressure monitoring, social needs support)
What this could lead to
If successful, this program could provide a practical way to improve blood pressure control in Black communities, reducing health disparities.
What could go wrong
This is an implementation study, not a test of a new drug. Success depends on how well clinics and patients adopt the program, and results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

UH3 IMPLEMENTATION PHASE (Years 4 - 7): INTERVENTION Inclusion Criteria: Patients are eligible if he/she: 1. identifies as Black (through EHR code or self-report) 2. is 18+ years of age 3. has a diagnosis of HTN (identified by ICD-10 codes for HTN) 4. prescribed an antihypertensive medication(s) 5. has a clinic BP \> 130/80 mmHg Exclusion Criteria: Patients will be ineligible for the study if they: 1. are deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks) 2. participate in other hypertension-related clinical trials 3. have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR) 4. plan to discontinue care at the site within the next 12 months; or 5. are pregnant or planning to become pregnant in the next 12 months IMPLEMENTATION EVALUATION 1. NYULH Primary care provider (MD/DO, NP), Clinical Director, Site Administrator, Medical Assistant, or administrative staff employed at the participating practices and interacts with at least five patients with a diagnosis of hypertension; or 2. NYULH Nurse case manager within centralized service; or 3. Staff and leadership of community- and faith-based organizations serving the Black community; or 4. NYULH Organizational leadership; or 5. NYULH Project Staff: Community Health Workers/CHW Supervisor/Practice Facilitators; and 6. Able and willing to provide consent Exclusion Criteria: 1\. Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension (HTN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension (HTN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.